Amanote Research
Register
Sign In
Nonhomologous End-Joining Can Be Pharmacologically Inhibited
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2013-004
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 3, 2013
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Nonhomologous DNA End Joining in Cell-Free Extracts
Journal of Nucleic Acids
Biochemistry
Molecular Biology
XRCC1 Suppresses Somatic Hypermutation and Promotes Alternative Nonhomologous End Joining inIghgenes
Journal of Experimental Medicine
Medicine
Allergy
Immunology
Ribonucleolytic Resection Is Required for Repair of Strand Displaced Nonhomologous End-Joining Intermediates
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage
Annual Review of Genetics
Genetics
BRCA2 Antagonizes Classical and Alternative Nonhomologous End-Joining to Prevent Gross Genomic Instability
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
A KRAS-NRF2-53BP1 Nonhomologous End-Joining Repair Pathway Mediates Oncogenic KRAS Radioresistance
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Hypersensitivity of Nonhomologous DNA End-Joining Mutants to VP-16 and ICRF-193
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Xlf1 Is Required for DNA Repair by Nonhomologous End Joining in Schizosaccharomyces Pombe
Genetics
Genetics
Bacterial Nonhomologous End Joining Ligases Preferentially Seal Breaks With a 3′-Oh Monoribonucleotide
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology